Acta Scientific NUTRITIONAL HEALTH (ISSN:2582-1423)

Volume 9 Issue 1 January 2025

Review Article

Nutraceutical-Pharmaceutical Synergy: Unlocking the Future of Precision Nutrition and Holistic Healthcare

Rwaida A Al Haidari[1]*, Mahmoud AH Mostafa[1,2]*, Aseel M Alayoubi[3], Haneen T Alharbi[3], Adel S Altarjami[3], Shatha S Alahmadi[3], Arwa A Aljohani[3] and Dina S Alnizari[3]

[1]Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah 41477, Saudi Arabia

[2]Department of Pharmacognosy, Faculty of Pharmacy, Al Azhar University, Assiut Branch, Assiut 71524, Egypt

[3]PharmD Program, Faculty of Pharmacy, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah 41477, Saudi Arabia

***Corresponding Author:** Mahmoud AH Mostafa, Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al Madinah Al Munawarah 41477, Saudi Arabia and Department of Pharmacognosy, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71526, Egypt.

Received: December 09, 2024

Published: December 23, 2024

Abstract

Chronic diseases, including cardiovascular disorders, metabolic syndromes, and neurodegenerative conditions, are complex and multifactorial, requiring innovative therapeutic strategies. The integration of nutraceuticals and pharmaceuticals is emerging as a synergistic approach to address these conditions by leveraging the complementary mechanisms of action of both modalities.

This review aims to evaluate the role of nutraceutical-pharmaceutical integration in enhancing therapeutic outcomes, focusing on advancements in delivery systems, functional foods, and the potential for personalized and precision healthcare applications.

A systematic search following PRISMA guidelines was conducted in PubMed, Scopus, and Web of Science databases for articles published between 2015 and 2023. Inclusion criteria focused on studies evaluating combined nutraceutical and pharmaceutical interventions for chronic, metabolic, or neurological diseases. Quality assessment of randomized and observational studies was performed using the Cochrane Risk of Bias tool and Newcastle-Ottawa Scale.

Eighty-two studies were synthesized, revealing that combining nutraceuticals with pharmaceuticals enhances therapeutic efficacy and reduces adverse effects. Key innovations in delivery systems, such as liposomal encapsulation and nanotechnology, improved the bioavailability and stability of bioactive compounds like curcumin and resveratrol. Functional foods, such as omega-3-enriched yogurts and polyphenol-fortified beverages, demonstrated improved patient compliance and measurable health benefits. Challenges include the standardization of nutraceutical formulations, potential drug-nutrient interactions, and cost barriers. Integrating nutraceuticals with pharmaceuticals represents a promising avenue for managing chronic diseases. Advances in technology and personalized approaches can bridge current gaps, offering scalable and sustainable healthcare solutions aligned with precision medicine principles.

Keywords: Nutraceuticals; Pharmaceuticals; Personalized Nutrition; Functional Foods; Chronic Diseases Omega-3 Fatty Acids; Curcumin

Introduction

Chronic diseases, including cardiovascular disorders, metabolic syndromes, and neurodegenerative conditions, remain the leading causes of global morbidity and mortality, contributing to over 70% of deaths worldwide (WHO, 2023) [1]. These conditions are multifactorial, involving complex interactions between genetic, environmental, and lifestyle factors, which complicates their management. Conventional pharmaceutical treatments are essential in controlling disease progression but often target isolated biochemical pathways. As a result, they frequently fail to address the underlying mechanisms driving chronic conditions, such as chronic inflammation, oxidative stress, and metabolic dysregulation [2-4]. Moreover, prolonged reliance on pharmaceuticals can lead to challenges such as drug resistance, adverse effects, and reduced patient adherence.

Nutraceuticals, bioactive compounds derived from natural sources like foods, medicinal plants, and microbial fermentation, have emerged as promising adjunct therapies. These compounds exhibit pleiotropic benefits by targeting multiple biochemical pathways, making them valuable tools in managing complex diseases. Their ability to address systemic health issues and modulate diverse physiological processes has positioned nutraceuticals as complementary agents to conventional pharmaceuticals.

In recent years, the integration of nutraceuticals with pharmaceutical regimens has gained traction as a strategy to enhance therapeutic outcomes and improve quality of life. By combining the targeted efficacy of pharmaceuticals with the systemic benefits of nutraceuticals, healthcare systems can achieve synergistic effects. Advances in omics technologies, such as genomics and microbiomics, along with innovations in delivery systems like nanotechnology and encapsulation techniques, have further expanded the potential of this integration. These advancements not only enhance the bioavailability and stability of nutraceuticals but also align with the principles of personalized and preventive medicine.

This review explores the evolving landscape of nutraceutical-pharmaceutical integration, highlighting evidence-based applications, advancements in delivery systems, and strategies for global adaptation. It emphasizes the potential of nutraceuticals to complement conventional treatments, addressing the multifactorial nature of chronic diseases and supporting the shift toward precision healthcare.

Materials and Methods

This review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Searches were conducted using PubMed, Scopus, and Web of Science databases for articles published between 2015 and 2023. Keywords included “nutraceuticals,” “pharmaceutical treatments,” “functional foods,” “genomics,” “microbiome,” and “personalized nutrition”.

Inclusion criteria

- Peer-reviewed articles evaluating nutraceuticals combined with pharmaceuticals.
- Studies addressing chronic, metabolic, or neurological conditions.
- Clinical trials, cohort studies, and mechanistic studies.
- Articles published in English.

Exclusion criteria

- Studies focusing solely on pharmaceutical or nutraceutical interventions without integration.
- Review articles lacking original data.
- Studies with a high risk of bias or limited methodological details.

A total of 162 articles were identified, of which 82 studies met the inclusion criteria following quality assessment using the Cochrane and Newcastle-Ottawa tools. Data on interventions, outcomes, and key findings were extracted for synthesis.

Quality assessment

The Cochrane Risk of Bias tool was applied to assess the quality of RCTs, while the Newcastle-Ottawa Scale evaluated observational studies. Only studies with low-to-moderate risk of bias were included.

Results

The integration of nutraceuticals with pharmaceuticals is transforming healthcare by offering synergistic solutions that address the multifactorial mechanisms underlying chronic diseases, neurological disorders, and metabolic dysfunctions. This section consolidates key findings from clinical trials, preclinical studies, and mechanistic research, with a focus on synergistic effects, advances in delivery systems, and global applicability.

Synergistic effects of nutraceuticals with pharmaceuticals

Omega-3 fatty acids and cardiovascular drugs

Omega-3 fatty acids exert their effects by reducing hepatic very-low-density lipoprotein (VLDL) synthesis, enhancing endothelial nitric oxide synthase (eNOS) activity, and suppressing pro-inflammatory cytokines such as IL-6 and TNF-α [5]. Clinical evidence from the REDUCE-IT trial demonstrated a 25% reduction in cardiovascular events when high-dose EPA (4 g/day) was combined with statin therapy [6,7]. Furthermore, recent studies have reported an additional 15% reduction in cardiovascular risks, particularly in patients with elevated triglycerides [8,9].

Curcumin and anti-inflammatory drugs

Mechanisms: Curcumin modulates NF-κB signaling, scavenges reactive oxygen species (ROS), and reduces inflammatory markers such as CRP and IL-6 [10,11]. Clinical Evidence: Chandran and Goel

(2012) demonstrated that curcumin alleviates rheumatoid arthritis symptoms as effectively as diclofenac, with fewer gastrointestinal side effects [12].

Probiotics and antidepressants

Mechanisms: Probiotics, such as Lactobacillus rhamnosus and Bifidobacterium breve, produce short-chain fatty acids (SCFAs) that reinforce blood-brain barrier integrity and reduce neuroinflammation [13-15]. Clinical Evidence: Gao., *et al.* (2023) observed a 20% greater reduction in depressive symptoms with probiotics and SSRIs, while Lukić., *et al.* (2019) reported a 30% reduction in depression severity scores with probiotic co-administration [16-19]. Table 1 presents examples of the synergistic effects observed between nutraceuticals and pharmaceuticals, highlighting their combined therapeutic benefits. Table 2 provides an overview of key clinical trials on nutraceuticals, summarizing their application, sample size, and outcomes in managing various health conditions.

Resveratrol and neuroprotective agents

Resveratrol, a polyphenol found in grapes and berries, activates sirtuin-1 (SIRT1), reduces oxidative stress, and enhances mitochondrial function, making it a promising adjunct for neuroprotective therapies.

Clinical evidence

Gu., *et al.* (2021) reported that high-dose resveratrol stabilized cerebrospinal fluid amyloid-beta levels and reduced neuroinflammation in Alzheimer's disease patients [20].

Case study

In preclinical Parkinson's disease models, resveratrol preserved dopaminergic neurons, reduced neuroinflammation, and improved motor function [21,22].

Table 1: Synergistic Effects Between Nutraceuticals and Pharmaceuticals.

Nutraceutical	Pharmaceutical Partner	Synergistic Effect
Omega-3 Fatty Acids	Statins	Reduces triglycerides, improves lipid profiles
Curcumin	NSAIDs	Enhances anti-inflammatory action, reduces GI side effects
Probiotics	SSRIs	Improves gut health, reduces depressive symptoms
Resveratrol	Neuroprotective agents	Reduces neuroinflammation, supports amyloid-beta clearance

Table 2: Summary of Clinical Trials on Nutraceuticals.

Study	Nutraceutical	Condition Studied	Sample Size	Outcome
REDUCE-IT Tria l(2020)	Omega-3 (EPA)	Cardiovascular disease	8179	25% reduction in major cardiovascular events [7]
Chandran and Goel (2012)	Curcumin	Rheumatoid arthritis	45	Comparable symptom relief to NSAIDs with fewer side effects [12]
Gao., *et al.* (2023)	Probiotics	Major depressive disorder	70	20% greater reduction in depressive symptoms with SSRIs [16].
Gu., *et al.* (2021)	Resveratrol	Alzheimerâ€™s disease	119	Stabilized amyloid-beta levels, reduced neuroinflammation

Advances in delivery systems for nutraceuticals

Liposomal curcumin

Mechanisms: Liposomal systems enhance curcumin's solubility and stability, facilitating uptake and anti-inflammatory effects [23]. Clinical Evidence: Liposomal curcumin reduced biomarkers like IL-6 in metabolic syndrome patients.

Nanoparticles for resveratrol

Mechanisms: Nanoparticles ensure sustained release and targeted delivery, protecting resveratrol from oxidative degradation [24].

Applications

In preclinical Parkinson's models, resveratrol improved motor function and reduced oxidative stress [25,26].

Solid lipid nanoparticles (SLNs)

Clinical evidence

SLNs increased curcumin's bioavailability by 3- to 5-fold compared to conventional formulations [27].

Table 3 provides an overview of delivery systems and advancements aimed at improving the bioavailability of nutraceuticals, highlighting their applications and associated benefits.



Figure 1: Integration of Nutraceuticals and Pharmaceuticals.

This figure illustrates the synergistic effects of combining nutraceuticals with pharmaceuticals. Key examples include omega-3 fatty acids, curcumin and probiotics. These combinations highlight the complementary mechanisms and therapeutic potential of nutraceutical-pharmaceutical integration for addressing multifactorial health challenges.

Table 3: Delivery Systems and Advancements in Bioavailability.

Technology	Application	Advantages
Liposomal Encapsulation	Improves curcumin bioavailability	Enhanced solubility and absorption
Nanoparticles	Protects resveratrol from degradation	Targeted delivery and sustained release
Solid Lipid Nanoparticles	Enhance delivery of omega-3s and curcumin	Controlled release, increased stability
Hydrogel Systems	Sustained release of polyphenols	Improved palatability and delivery in functional foods

Functional foods as nutraceutical delivery vehicles

Omega-3-fortified yogurts and antihypertensives

Clinical evidence

Zhang., *et al.* (2021) showed a 12% reduction in systolic blood pressure with omega-3-fortified yogurt combined with antihypertensives [28].

Polyphenol-enriched beverages

Clinical evidence

Francini-Pesenti., *et al.* (2019) demonstrated improved insulin sensitivity and reduced oxidative stress in individuals consuming polyphenol-enriched beverages [29].

Fiber-Enriched probiotic beverages

Case study

Research studies found that fiber-enriched probiotic beverages reduced waist circumference by 15% and improved insulin sensitivity over 16 weeks [30,31].

Green tea enriched with catechins and resveratrol in cardiovascular health

Green tea, enriched with bioactive compounds such as catechins and resveratrol, has shown marked benefits in improving cardiovascular health outcomes when combined with pharmaceutical interventions.

Case study

Sone., *et al*. (2011) conducted an 8-week randomized controlled trial where green tea enriched with catechins, and resveratrol reduced systolic blood pressure by 10 mmHg and improved lipid profiles in hypertensive patients [32].

Mechanisms

Catechins and resveratrol synergistically reduce oxidative stress, enhance endothelial NO production, and regulate lipid metabolism, providing dual benefits for blood pressure control and cardiovascular protection [33,34].

Opportunities for global adaptation

Regional nutraceuticals

- **Asia:** Green tea catechins align with dietary habits and reduce cardiovascular risks [35].
- **Africa:** Millet-based functional foods combat micronutrient deficiencies in low-income populations [36].
- **South America:** Acai berry and grape-derived polyphenols, abundant in the region, show antioxidant and anti-inflammatory properties [37].

Cultural variability

Different delivery formats cater to regional preferences. For example, green tea enriched with resveratrol aligns well with Asian diets, while cacao-derived polyphenols are culturally significant in South America, and wine-based polyphenols are widely studied in European populations [38,39].

Demographic tailoring

Lactose-intolerant populations and Elderly Populations: Formulations targeting enhanced absorption address gastrointestinal declines in older adults [40-43].

Emerging nutraceuticals

Expanding research on emerging nutraceuticals broadens therapeutic options:

- **Quercetin**: A potent antioxidant with immunomodulatory properties that complements pharmaceutical therapies in chronic disease management [44,45].
- **Sulforaphane**: Derived from cruciferous vegetables, it activates detoxification pathways and reduces oxidative stress [46].
- **Beta-Glucans**: Soluble fibers from oats and barley improve cholesterol levels and immune function, particularly in metabolic syndrome [47,48].

Discussion

The integration of nutraceuticals with pharmaceuticals represents a transformative shift in modern healthcare, offering innovative solutions to address complex health challenges such as chronic diseases, metabolic dysfunctions, and neurodegenerative conditions. By targeting multiple pathways, including inflammation, oxidative stress, and metabolic dysregulation, nutraceuticals complement the targeted actions of conventional pharmaceuticals, providing a holistic and multifaceted therapeutic approach.

Synergistic potential of nutraceuticals

Nutraceuticals such as omega-3 fatty acids, curcumin, resveratrol, and probiotics have demonstrated significant synergistic effects when combined with pharmaceuticals. For instance, omega-3s have shown cardioprotective effects, enhancing lipid metabolism and reducing inflammation, as evidenced by the REDUCE-IT trial, which reported a 25% reduction in cardiovascular events with high-dose EPA supplementation alongside statins [6]. Similarly, curcumin improves the efficacy of NSAIDs by modulating inflammatory pathways, while probiotics enhance mental health outcomes through gut-brain axis modulation. These examples highlight the potential of nutraceutical-pharmaceutical combinations to improve therapeutic efficacy and reduce adverse effects.

Advances in delivery systems and functional foods

Advancements in delivery technologies such as liposomal encapsulation, nanoparticles, and solid lipid nanoparticles (SLNs) have addressed key limitations of nutraceuticals, including poor solubility, stability, and bioavailability. For instance, liposomal curcumin has been shown to significantly reduce biomarkers such as IL-6 in metabolic syndrome patients, while nanoparticle-based systems have improved the stability and efficacy of resveratrol in neurodegenerative models [20,21]. These technologies enhance the clinical utility of nutraceuticals, enabling them to complement pharmaceuticals effectively.

Functional foods enriched with bioactives, such as omega-3-fortified yogurts and polyphenol-enriched beverages, represent another innovative approach to integrating nutraceuticals into daily routines. These foods improve compliance and scalability, offering region-specific and culturally acceptable solutions. For example, omega-3-fortified yogurt has been shown to reduce systolic blood pressure when combined with antihypertensive medications [25].

Challenges and future directions

Despite these advancements, challenges persist in the widespread adoption of nutraceutical-pharmaceutical integration. Key barriers include:

- **Standardization:** Variability in sourcing, processing, and formulation affects product consistency and efficacy. Regulatory frameworks and good manufacturing practices are essential to address these issues.
- **Potential Interactions:** Nutraceuticals may alter the pharmacokinetics or pharmacodynamics of pharmaceuticals, requiring rigorous pharmacokinetic studies and healthcare professional education.

- **Accessibility and Cost:** Advanced delivery systems and fortified functional foods often remain expensive, limiting their availability in low-income populations. Innovations in cost-effective production methods and public-private partnerships could mitigate these barriers.

Looking ahead, leveraging artificial intelligence (AI) and emerging technologies offers exciting opportunities to optimize nutraceutical-pharmaceutical integration. AI-powered analytics can tailor interventions to individual needs, predict potential interactions, and support population-level health initiatives. Additionally, advancements in biopolymer-based nanocarriers and stimuli-responsive delivery systems promise to further improve nutraceutical efficacy and personalization [49-51].

Expanding the application of nutraceuticals to address emerging health challenges, such as cognitive decline, mental health disorders, and immune modulation, aligns with the growing emphasis on personalized and preventive medicine. Functional foods targeting these areas, as well as region-specific formulations, could further enhance their accessibility and global impact.

Conclusion

The convergence of nutraceuticals and pharmaceuticals marks a transformative step in precision healthcare and personalized nutrition. By addressing multifactorial disease mechanisms, this integrative approach enhances therapeutic efficacy, mitigates adverse effects, and provides holistic solutions for managing chronic diseases, metabolic dysfunctions, and neurodegenerative conditions. The synergistic potential of bioactive compounds such as omega-3 fatty acids, curcumin, resveratrol, and probiotics exemplifies how nutraceuticals complement conventional pharmaceuticals to improve patient outcomes and quality of life.

Innovations in delivery systems, including liposomal encapsulation and nanotechnology, have addressed critical challenges such as poor bioavailability and patient compliance, making the integration of nutraceuticals and pharmaceuticals more feasible and effective. Additionally, fortified functional foods and AI-driven personalized plans offer innovative strategies to optimize adherence and achieve precision healthcare goals.

Despite these advancements, challenges persist, including the standardization of nutraceutical formulations, potential drug-nutrient interactions, and improving accessibility, particularly in resource-limited settings. Addressing these issues requires robust interdisciplinary collaboration among researchers, clinicians, policymakers, and industry stakeholders to establish regulatory frameworks, ensure consistency, and develop scalable, cost-effective solutions.

Future directions include leveraging emerging technologies such as biopolymer-based nanocarriers and AI-powered analytics to further refine delivery systems and personalization. Expanding the applications of nutraceuticals to target emerging health challenges—such as gut-brain axis interactions, mental health, and immune modulation—offers significant opportunities for innovation.

In summary, the integration of nutraceuticals and pharmaceuticals represents a paradigm shift in healthcare, with the potential to improve therapeutic outcomes, promote sustainability, and pave the way for a more effective, patient-centered, and globally adaptable healthcare system.

Conflict of Interest

No conflicts of interest are associated with this work.

Glossary

- **AI (Artificial Intelligence):** Technology used to optimize nutraceutical-pharmaceutical integration through data analysis, intervention customization, and prediction of interactions.
- **Beta-Glucans:** Soluble fibers from oats and barley that help reduce cholesterol levels, boost immune function, and manage metabolic syndrome.
- **Cardiovascular Disorders:** Diseases affecting the heart and blood vessels, including coronary artery disease and hypertension.
- **Catechins:** Bioactive polyphenols commonly found in green tea, known for their antioxidant properties and cardiovascular benefits.
- **Chronic Diseases:** Long-term medical conditions such as cardiovascular disorders, metabolic syndromes, and neurodegenerative diseases.
- **Curcumin:** A polyphenolic compound found in turmeric, recognized for its anti-inflammatory, antioxidant, and disease-modulating effects.
- **Delivery Systems:** Methods and technologies such as liposomal encapsulation, nanoparticles, and solid lipid nanoparticles that improve the bioavailability, stability, and efficacy of nutraceuticals.
- **Functional Foods:** Foods enriched with bioactive ingredients, such as omega-3-fortified yogurts and polyphenol-enriched beverages, to improve health outcomes and compliance.
- **Genomics:** The study of an organism's genes, aiding in the development of personalized interventions for nutraceutical-pharmaceutical integration.
- **Gut-Brain Axis:** The bidirectional communication network between the gastrointestinal system and the brain, influenced by probiotics and dietary interventions.
- **Hydrogel Systems:** Advanced delivery systems for controlled release and improved stability of nutraceuticals.
- **IL-6 (Interleukin-6):** An inflammatory cytokine involved in the body's immune response, targeted by nutraceuticals like curcumin and omega-3s.

- **Lactobacillus rhamnosus:** A probiotic strain that supports gut health, reinforces blood-brain barrier integrity, and reduces neuroinflammation.
- **Metabolic Syndromes:** A cluster of conditions, including insulin resistance and obesity, that increase the risk of heart disease, diabetes, and stroke.
- **Nanoparticles:** Tiny carriers used to improve the stability, bioavailability, and targeted delivery of nutraceuticals such as resveratrol.
- **NF-κB (Nuclear Factor Kappa B):** A protein complex involved in regulating inflammation, modulated by nutraceuticals like curcumin.
- **Omega-3 Fatty Acids:** Essential fatty acids with anti-inflammatory and cardioprotective effects, commonly found in fish oil and algae.
- **Personalized Nutrition:** Tailoring dietary recommendations and nutraceutical-pharmaceutical interventions based on individual genetic, lifestyle, and microbiome profiles.
- **Polyphenols:** Plant-based compounds with antioxidant and anti-inflammatory properties, such as resveratrol and catechins.
- **Precision Medicine:** A healthcare approach that considers individual variability in genes, environment, and lifestyle to optimize treatment.
- **Probiotics:** Live microorganisms, such as Lactobacillus and Bifidobacterium species, that provide health benefits by modulating gut microbiota and systemic inflammation.
- **Reactive Oxygen Species (ROS):** Highly reactive molecules involved in oxidative stress, neutralized by antioxidants like curcumin and polyphenols.
- **REDUCE-IT Trial:** A clinical trial demonstrating a 25% reduction in cardiovascular events with high-dose EPA combined with statins.
- **Resveratrol:** A polyphenol found in grapes and berries, recognized for its antioxidant, anti-inflammatory, and neuroprotective properties.
- **Short-Chain Fatty Acids (SCFAs):** Metabolic byproducts of gut microbiota fermentation that improve gut-brain barrier integrity and reduce inflammation.
- **Solid Lipid Nanoparticles (SLNs):** Advanced delivery systems for enhancing the bioavailability and controlled release of lipophilic nutraceuticals.
- **Standardization:** The process of ensuring consistent quality, efficacy, and safety in nutraceutical formulations through regulatory frameworks.
- **Sustainability:** Developing healthcare solutions that are scalable, affordable, and environmentally responsible, such as sustainable nutraceutical sourcing and production.
- **VLDL (Very Low-Density Lipoprotein):** A type of lipoprotein involved in lipid transport, reduced by omega-3 fatty acids to improve cardiovascular health.
- **WHO (World Health Organization):** A specialized agency of the United Nations focused on international public health, providing key statistics on chronic diseases.

Bibliography

1. World Health Organization. "Noncommunicable Diseases: Key Facts". WHO (2023).
2. Orlando F A and A G Mainous III. "Editorial: Inflammation and Chronic Disease". *Frontiers in Medicine* 11 (2024): 1434533.
3. Pahwa R., *et al*. "Chronic Inflammation". StatPearls, updated 7 Aug. 2023, StatPearls Publishing (2024).
4. Shabbir U., *et al*. "The Potential Role of Polyphenols in Oxidative Stress and Inflammation Induced by Gut Microbiota in Alzheimer's Disease". *Antioxidants* 10.9 (2021): 1370.
5. Calder P C. "Omega-3 Fatty Acids and Inflammatory Processes: From Molecules to Man". *Biochemical Society Transactions* 45.5 (2017): 1105-1115.
6. Bhatt Deepak L., *et al*. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia". *New England Journal of Medicine* 380.1 (2019): 11-22.
7. Boden WE., *et al*. "Profound Reductions in First and Total Cardiovascular Events with Icosapent Ethyl in the REDUCE-IT Trial". *European Heart Journal* 41.24 (2020): 2304-2312.
8. Jun J E., *et al*. "Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia". *Diabetes and Metabolism Journal* 44.1 (2020): 78-90.
9. Kris-Etherton P M., *et al*. "Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids". *Methodist Debakey Cardiovascular Journal* 15.3 (2019): 171-178.
10. Qiu L., *et al*. "Effects of Dietary Polyphenol Curcumin Supplementation on Metabolic, Inflammatory, and Oxidative Stress Indices in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis". *Frontiers in Endocrinology* 14 (2023): 1216708.
11. Rattis B A C., *et al*. "Curcumin as a Potential Treatment for COVID-19". *Frontiers in Pharmacology* 12 (2021): 675287.
12. Chandran B and A Goel. "A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis". *Phytotherapy Research* 26.11 (2012): 1719-1725.
13. Margolis K G., *et al*. "The Microbiota-Gut-Brain Axis: From Motility to Mood". *Gastroenterology* 160.5 (2021): 1486-1501.
14. Nakhal MM., *et al*. "The Microbiota-Gut-Brain Axis and Neurological Disorders: A Comprehensive Review". *Life* 14.10 (2024): 1234.

15. Fusco W., *et al*. "Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota". *Nutrients* 15.9 (2023): 2211.

16. Gao J., *et al*. "Probiotics for the Treatment of Depression and Its Comorbidities: A Systematic Review". *Frontiers in Cellular and Infection Microbiology* 13 (2023): 1167116.

17. Lukić I., *et al*. "Antidepressants Affect Gut Microbiota and Ruminococcus Flavefaciens Is Able to Abolish Their Effects on Depressive-Like Behavior". *Translational Psychiatry* 9 (2019): 133.

18. Xie S., *et al*. "Lacticaseibacillus rhamnosus KY16 Improves Depression by Promoting Intestinal Secretion of 5-HTP and Altering the Gut Microbiota". *Journal of Agricultural and Food Chemistry* 72.39 (2024): 21560-21573.

19. Yong S J., *et al*. "Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential". *Frontiers in Neuroscience* 13 (2020): 1361.

20. Gu J., *et al*. "Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial". *Neurology and Therapy* 10.2 (2021): 905-917.

21. Dos Santos Michele Goulart., *et al*. "Neuroprotective Effects of Resveratrol in In Vivo and In Vitro Experimental Models of Parkinson's Disease: A Systematic Review". *Neurotoxicity Research* (2022): 1-27.

22. Pang M., *et al*. "Molecular Understanding of the Translational Models and the Therapeutic Potential of Natural Products for Parkinson's Disease". *Biomedicine and Pharmacotherapy* 155 (2022): 113718.

23. Li K X., *et al*. "Curcumin-Loaded Long-Circulation Liposomes Ameliorate Insulin Resistance in Type 2 Diabetic Mice". *International Journal of Nanomedicine* 19 (2024): 12099-12110.

24. Ali M., *et al*. "Recent Developments in Nanoparticle Formulations for Resveratrol Encapsulation as an Anticancer Agent". *Pharmaceuticals* 17.1 (2024): 126.

25. Chung IM., *et al*. "Resveratrol Nanoparticles: A Promising Therapeutic Advancement over Native Resveratrol". *Processes* 8.4 (2020): 458.

26. Vaiserman A., *et al*. "Nanodelivery of Natural Antioxidants: An Anti-aging Perspective". *Frontiers in Bioengineering and Biotechnology* 7 (2020): 447.

27. Yeo S., *et al*. "Solid Lipid Nanoparticles of Curcumin Designed for Enhanced Bioavailability and Anticancer Efficiency". *ACS Omega* 7.40 (2022): 35875-35884.

28. Zhang X., *et al*. "Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials". *Journal of the American Heart Association* 11.11 (2022): e025071.

29. Francini-Pesenti F., *et al*. "Potential Role of Phytochemicals in Metabolic Syndrome Prevention and Therapy". *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 12 (2019): 1987-2002.

30. Mohr AE., *et al*. "Gut Microbiome Remodeling and Metabolomic Profile Improves in Response to Protein Pacing with Intermittent Fasting versus Continuous Caloric Restriction". *Nature Communications* 15 (2024): 4155.

31. Cronin P., *et al*. "Dietary Fibre Modulates the Gut Microbiota". *Nutrients* 13.5 (2021): 1655.

32. Sone T., *et al*. "Randomized Controlled Trial for an Effect of Catechin-Enriched Green Tea Consumption on Adiponectin and Cardiovascular Disease Risk Factors". Food and Nutrition Research 55 (2011).

33. Sheng Y., *et al*. "Catechins: Protective Mechanism of Antioxidant Stress in Atherosclerosis". *Frontiers in Pharmacology* 14 (2023): 1144878.

34. Breuss JM., *et al*. "Resveratrol and Its Effects on the Vascular System". *International Journal of Molecular Sciences* 20.7 (2019): 1523.

35. Zamani M., *et al*. "The Effects of Green Tea Supplementation on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis". *Frontiers in Nutrition* 9 (2023): 1084455.

36. Popoola J O., *et al*. "Nutritional, Functional, and Bioactive Properties of African Underutilized Legumes". *Frontiers in Plant Science* 14 (2023): 1105364.

37. Laurindo LF., *et al*. "Açaí (Euterpe oleracea Mart.) in Health and Disease: A Critical Review". *Nutrients* 15.4 (2023): 989.

38. Aryal D., *et al*. "Dietary Phenolic Compounds as Promising Therapeutic Agents for Diabetes and Its Complications: A Comprehensive Review". *Food Science and Nutrition* (2024).

39. Ohishi T., *et al*. "The Beneficial Effects of Principal Polyphenols from Green Tea, Coffee, Wine, and Curry on Obesity". *Molecules* 26.2 (2021): 453.

40. García-Maldonado E., *et al*. "Changes in Fatty Acid Levels after Consumption of a Novel Docosahexaenoic Supplement from Algae: A Crossover Randomized Controlled Trial in Omnivorous, Lacto-Ovo Vegetarians and Vegans". *European Journal of Nutrition* 62.4 (2023): 1691-1705.

41. Li A., *et al*. "Advances in Low-Lactose/Lactose-Free Dairy Products and Their Production". Foods 12.13 (2023): 2553.

42. Chengolova Z., *et al*. "How to Keep Lactose Avoiders Healthy". *Dairy* 5.4 (2024): 702-726.

43. Cristina N M and Lucia D. "Nutrition and Healthy Aging: Prevention and Treatment of Gastrointestinal Diseases". *Nutrients* 13.12 (2021): 4337.

44. Gasmi A., *et al*. "Natural Ingredients to Improve Immunity". *Pharmaceuticals* 16.4 (2023): 528.

45. Patil K., *et al*. "Immunomodulation Property of Antioxidants". *Antioxidants as Nutraceuticals*, Apple Academic Press (2025): 95-124.

46. Cascajosa-Lira A., *et al*. "Protective Effects of Sulforaphane Against Toxic Substances and Contaminants: A Systematic Review". *Phytomedicine* 130 (2024): 155731.

47. Singla A., *et al*. "Beta-Glucan as a Soluble Dietary Fiber Source: Origins, Biosynthesis, Extraction, Purification, Structural Characteristics, Bioavailability, Biofunctional Attributes, Industrial Utilization, and Global Trade". *Nutrients* 16.6 (2024): 900.

48. Sima P., *et al*. "β-Glucans and Cholesterol (Review)". *International Journal of Molecular Medicine* 41.4 (2018): 1799-1808.

49. Majumder J and T Minko. "Multifunctional and Stimuli-Responsive Nanocarriers for Targeted Therapeutic Delivery". *Expert Opinion on Drug Delivery* 18.2 (2021): 205-227.

50. Amiri A., *et al*. "Exosomes as Bio-Inspired Nanocarriers for RNA Delivery: Preparation and Applications". *Journal of Translational Medicine* 20.1 (2022): 125.

51. Serrano D R., *et al*. "3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals". *Pharmaceutics* 15.2 (2023): 313.